OXIDE

Supplementary Explanatory Materials for the Fiscal Year Ended February 28, 2023

April 14, 2023 TSE Growth Market: 6521 OXIDE Corporation

Copyright: 2023 OXIDE Corporation. All Rights Reserved

I will now explain our financial results for the fiscal year ended February 28, 2023.

Contents

FY2023 Financial Results

Results and financial figures Details by business Results vs the plan for FY2023 Topics

FY2024 Forecasts

Medium-Term Management Plan (consolidated)

This material was not prepared for the purpose of soliciting investments in securities issued by the Company.

The information herein is based on the Company's assumptions and beliefs at the time of preparation. No guarantee or promise is made as to the accuracy or completeness thereof.

The information includes risks, economic trends, industry demand, and other uncertainties that may affect actual results.

Therefore, the Company's forecasts and the actual results may differ materially. Thank you for your understanding.

The amounts in this material are rounded down to the indicated unit, and percentages are rounded off to the indicated unit. Therefore, the total of the breakdown and the actual total may not be the same.

opyright: 2023 OXIDE Corporation. All Rights Reserved.

I'll start with an overview.

After that, I will move on to the forecasts for the fiscal year ending February 29, 2024.

Results and percentage of achievement of full-year forecasts

OXIDE

FY2023 Financial I

FY2024 Forecasts

Net sales increased for the sixth consecutive fiscal year, and ordinary profit increased for the fifth consecutive fiscal year, both reaching record highs.

(Million yen)


	FY2/22	1Q	2Q	3Q	4Q	FY2/23	YoY	Previous forecast (Jan. 13)	Achievement
Net sales	4,756	1,419	1,541	1,459	1,331	5,752	+20.9%	5,870	98.0%
Gross profit	1,630	703	638	460	476	2,279	+39.8%	2,210	103.1%
SG&A	1,033	378	418	507	438	1,742	+68.6%	1,692	103.0%
Of which, R&D expense	315	134	182	202	155	675	+114.2%	682	99.0%
Operating profit	596	324	220	-46	38	537	-10.0%	516	104.1%
Non-operating income/loss	2	28	12	-3	109	150	+6731.8%	34	443.6%
Ordinary profit	598	353	233	0	147	687	+14.8%	550	125.1%
Total depreciation and amortization	269	74	86	93	100	356	+32.2%	371	96.1%

Copyright: 2023 OXIDE Corporation. All Rights Reserved

Let's look at the results and the percentage of achievement of full-year forecasts.

Net sales were 5,752 million yen, up 20.9% from the previous year; operating profit was 537 million yen, down 10% from the previous year; and ordinary profit was 687 million yen, up 14.8% from the previous year.


Net sales increased for the sixth consecutive fiscal year, and ordinary profit increased for the fifth consecutive fiscal year, both reaching record highs.



Next, let's look at performance and results versus management indicators.

We have set forth management indicators of 20% in net sales growth and an operating margin of 10%.

In FY2023, we achieved 20% growth in net sales, but the operating margin fell short by 0.7%.




Next, let's look at the Balance Sheet.

Total assets increased by 2,081 million yen from 8,710 million yen at the end of FY2022 to 10,791 million yen at the end of FY2023.

The breakdown of the increase is 436 million yen in work in process, 1,369 million in non-current assets, and 276 million yen in other assets.

The 1,440 million yen increase in liabilities was offset by a 641 million yen increase in net assets.



Next, let's look at cash flows.


Operating cash flows were a negative 119 million yen due to an increase in inventory assets for increased production.

Investing cash flows were a negative 1,732 million yen due to capital investment in the construction of factories No. 4 and No. 5 and investment and loans.

Financing cash flows were a positive 1,121 million yen owing to an increase in borrowings, primarily for capital expenditures.

Free cash flows were a negative 1,851 million yen.


Now, let's move on to performance by business and industry trends.



First, I will give the breakdown of net sales by business.

The Semiconductor business accounted for 56% of total sales in the fiscal year ended February 28, 2023, the Healthcare business 31%, and the Optical Measurement & Frontier Technology business 13%.

The Semiconductor business, which has demonstrated remarkable market growth and market share expansion, increased by around 5% from the previous year.



Next, let's look at the Semiconductor business.


Right now, the semiconductor market is in decline worldwide.

However, with the construction of state-of-the-art semiconductor factories and the trend toward miniaturization, sales of our laser systems remained strong in the fiscal year under review.

Net sales were up 31.4% to 3,239 million yen, contributing significantly to the overall increase in sales.

The problematic pass rates for some components, which were mentioned at the time of the announcement of third quarter financial results, continue to bounce back to where they were before the problem.

We will work on strengthening the supply chain based on this lesson.




Next, let's look at the net sales trend in the Semiconductor business.

Overall, the Semiconductor business sales increased 31.4% from the previous fiscal year owing to strong demand for new lasers. The business has grown by more than 30% over the past three fiscal years.

Of these sales, maintenance sales for laser systems were down 9.5% from the previous year as a result of prioritizing the manufacture of new lasers.

The laser system went into mass production in the fiscal year ended February 28, 2021, so maintenance demand is expected to increase in earnest starting in this fiscal year.




Next up are orders received and the order backlog in the Semiconductor business.

Orders received in the fiscal year ended February 28, 2023 fell to 1,610 million yen in the second half of the year, compared to 2,283 million yen in the first half.

The reason for this was temporarily adjusting new orders to focus on solving a problem with some procured parts. We are currently taking orders normally.

The order backlog at the end of the year was 3,118 million yen, an increase from the end of the first half.


Next, let's look at the Healthcare business.



3Q net sales hit a record high in the Healthcare business.

However, 4Q net sales were weak due to inventory and production adjustments by customers.


As a result, net sales were up 3.5% from the previous year to 1,772 million yen.



As for the healthcare market, we have high expectations for progress in the market for brain PET scanner.

Medicine for the treatment of Alzheimer's disease co-developed by Eisai and Biogen was approved by the U.S. FDA on January 6. Applications for approval have also been submitted in Europe and Japan.


As the medicine spreads, brain PET scanner will be needed. In the fiscal year ended February 28, 2023, we made sales to research institutions both in Japan and abroad, so we expect further revenue growth.



In the Optical Measurement & Frontier Technology business, we are providing solutions that leverage our strengths and creating new businesses.


In the fiscal year ended February 28, 2023, spot sales to research institutions contributed to a 27.9% increase in net sales from the previous fiscal year to 7,410 million yen.

Next, we move on to personnel, R&D, and capital investment expenses.




First, in regard to personnel, hiring proceeded according to plan, and the new hires were primarily assigned to the Semiconductor business.

The number of employees at fiscal year-end was up 26.3% from the fiscal year ended February 28, 2022 to 264.



Next, we invested 675 million yen in R&D, up 114.3% from the fiscal year ended February 28, 2022.

We are focusing our investment on power semiconductor-related R&D, an area where we expect growth in the future.



Next, we recorded 1,355 million yen in capital investment expense, up 35.1% from the fiscal year ended February 28, 2022.

The 210 million yen difference from the plan will be recorded in the fiscal year ending February 29, 2024.


Горісѕ		OXI					
		FY2023 Financial Results FY2024 Forec					
	May	Capital and business alliance with LQUOM, Inc.					
	,	22nd Ordinary General Meeting of Shareholders					
	Aug	Organizational change (new establishment of Quantum and Communication Center and New Business Promotion Office)					
2022	Sep	Received Early Edge Award in Award for Academic Startups together with LQUOM and Yokohama National University					
	Oct	Participated in 3rd Quantum Computing Expo					
	Nov -	Received Technology Award from Japanese Association for Crystal Growth					
		Decided to raise employee wages to keep pace with inflation					
	Dec	Board of Directors resolution on stock split					
	Jan -	Received Excellence Prize at 9th Monodzukuri Nippon Grand Awards					
		Agreement on acquiring Raicol Crystals Ltd. shares (making it a subsidiary) ★					
		Decision on additional investment in LQUOM					
0000		Participated in Photonics West					
2023	Feb	Investment in HTCS					
	Mar	Acquisition of Raicol Crystals Ltd.					
		Partnership with National Institute for Materials Science (NIMS) for startup support ★					
		Completion of construction of factories No. 4 and No. 5 ★					

Next, let's look at the topics.



On March 1, we made Israel-based Raicol a wholly owned subsidiary.

With Raicol we set theses targets and will work to achieve them.



By making Raicol a subsidiary, we have added Space & Defense, Medical Aesthetics, and Energy to our business fields and will strengthen the Quantum field.

Combining our strengths with those of Raicol, we will strive to become a leading global company in the field of optics.



At the end of March, we completed construction of factories No. 4 and No. 5 to promote business expansion.

Factory No. 4 will be a mass production plant to meet maintenance demands in the Semiconductor business, and Factory No. 5 will be a plant for developing mass production technology for power silicon carbide (SiC) semiconductors.



We signed a memorandum of understanding with the National Institute for Materials Science (NIMS).

We will support social implementation of research results by returning the management expertise we have cultivated over the years in the deep-tech field.

FY2023 Financial Results Results and financial figures Details by business Results vs the plan for FY2023 Topics FY2024 Forecasts Financial forecasts (non-consolidated) Financial forecasts (consolidated) Financial forecasts (consolidated) Medium-Term Management Plan (consolidated) Net sales forecasts by business (consolidated) Other plans (consolidated) Other plans (consolidated) This material was not prepared for the purpose of soliding investments in securities issued by the Company The information herein is based on the Company's assumptions and beliefs at the time of preparation. No guarantee or promise is made as to the accuracy or completeness thereof. The information herein is based on the Company's assumptions and beliefs at the time of preparation. No guarantee or promise is made as to the accuracy or completeness thereof. The information includes risk, economic trends, industry demand, and other uncertainties that may affect actual results. Therefore, the Company's forecasts and the actual results may differ materially. Thank you for your understanding. The amounts in this material are rounded down to the indicated unit, and percentages are rounded off to the indicated unit. Therefore, the total of the breskdown and the actual total may not be the same. Copyright: 2023 OXIDE Corporation. All Rights Reserved.

Next, let's take a look at the forecasts for the fiscal year ending February 29, 2024.

Financial forecasts (Non-consolidated) for FY2024

OXIDE

FY2023 Financial Results

FY2024 Forecasts

■ We expect a 26.8% increase in net sales, a 26.8% increase in operating profit, and a 37.4% increase in ordinary profit.

(Million yen)

	FY2/23			FY2/24	VeV		
	F12/23	1Q	2Q	3Q	4Q	F12/24	YoY
Net sales	5,752	1,315	1,718	2,011	2,250	7,294	+26.8%
Gross profit	2,279	368	650	788	971	2,777	+21.8%
SG&A	1,742	582	506	518	490	2,095	+20.3%
Of which, R&D expense	675	243	196	205	170	813	+20.5%
Operating profit	537	-214	144	270	481	681	+26.8%
Non-operating income/loss	150	85	-9	176	11	263	+74.9%
Ordinary profit	687	-129	135	446	492	945	+37.4%
Total depreciation and amortization	356	107	122	139	147	514	+44.3%

Copyright: 2023 OXIDE Corporation. All Rights Reserved

22

First up are the non-consolidated forecasts.

We expect net sales of 7,294 million yen, up 26.8% from the previous year; operating profit of 681 million yen, up 26.8% from the previous year; and ordinary profit of 945 million yen, up 37.4% from the previous year.

These forecasts are weighted toward the second half of the year, and sales are expected to increase due to the expansion of the Yokohama manufacturing facility and the start of operations at Factory No. 4 in the Semiconductor business.

Financial forecasts (Consolidated) for FY2024

OXIDE

EV2023 Financial Posulte

Profit and loss from Raicol are included from 2Q. Operating profit is concentrated in 2H.

(Million yen)

		Reference:					
	1Q (Non- consolidated)	2Q (Consolidated)	3Q (Consolidated)	4Q (Consolidated)	FY2/24 (Consolidated)	FY2/23 (Non- consolidated)	
Net sales	1,315	2,183	2,527	2,745	8,773	5,752	
Gross profit	385	890	1,053	1,222	3,554	2,279	
SG&A	576	655	693	679	2,603	1,742	
Of which, R&D expense	242	256	289	252	1,039	675	
Additional expenses associated with consolidation*	38	145	145	147	476	-	
Operating profit	-229	90	215	395	471	537	
Non-operating income/loss	68	-34	158	-11	181	150	
Ordinary profit	-161	56	373	384	652	687	

Calculated based on an exchange rate of 130 yen to the dollar and 37.7 yen to the new shekel.

Copyright: 2023 OXIDE Corporation. All Rights Reserved

2

Next are the consolidated forecasts.

We expect net sales of 8,773 million yen, operating profit of 471 million yen, and ordinary profit of 652 million yen.

Raicol's statement of income will be included in the consolidated results starting in the second quarter.


Additional expenses of 476 million yen have been recorded in relation to the consolidation this year.

The breakdown is 206 million yen in amortization of goodwill, 158 million yen in stock compensation expense, 68 million yen in PMI-related expenses, and 43 million yen in adjustments for differences in accounting standards.

As for quarterly operating profit, we expect it to be weighted toward the second half, starting out at a 229 million yen loss in the first quarter, but increasing to a positive 395 million yen in the fourth quarter.

Next, let's turn our attention to the Medium-Term Management Plan.


^{*} Additional costs associated with consolidation include amortization of goodwill (206 million yen), stock compensation expense (158 million yen), PMI-related expenses (68 million yen), and differences in accounting standards (43 million yen).



Our Medium-Term Management Plan was not included in our disclosures before, but we felt it would be beneficial to our shareholders and investors to present a three-year medium-term management plan that reflects the acquisition of Raicol.


We expect a substantial increase in net sales putting us at a record high in the fiscal year ending February 29, 2024.

The operating margin will decline due to M&A-related expenses, but we plan to achieve an operating margin in excess of 10% in the fiscal year ending February 28, 2026.




Next, let's take a look at the forecasts by business.

The addition of Factory No. 4 will increase production capacity of the Semiconductor business. This will also allow us to meet the continued strong demand for new lasers and increasing demand for maintenance. Furthermore, the portion carried over from the previous fiscal year will also contribute to the forecast, resulting in net sales of 4,978 million yen, up 53.7% from the previous year.




In the Healthcare business, sales of PET scanning machines for cancer diagnosis are expected to decline by 20% due to the global economic slowdown. On the other hand, sales of PET scanning machines for Alzheimer's disease diagnosis are on the rise, so we expect overall net sales to be down just 2.9% to 1,721 million yen.




In regard to the Optical Measurement & Frontier Technology business, we changed the name to the Frontier Technology business based on the fact that it includes more and more non-measurement fields of application.

We expect sales in the Frontier Technology business to increase by 179.8% to 2,073 million yen. We expect a significant increase in net sales this fiscal year as a result of making Raicol a subsidiary.




We plan to increase personnel by 65 people. Most of these will be assigned to the Semiconductor business.



This year, we plan to spend 1,039 million yen on R&D.

Continuing our efforts from the previous year, we will focus on accelerating development of power semiconductors.



We plan capital investment of 2,684 million yen.

It will mostly be allocated to mass production equipment at factories No. 4 and No. 5.



https://www.opt-oxide.com

Copyright: 2023 OXIDE Corporation. All Rights Reserved

